PSP001

**PSP001** is an investigational long-acting interferon lambda chimera being developed by Prosit Sole Biotechnology as an antiviral biologic. Publicly available descriptions indicate it is administered as an injection and is intended to act as an agonist of the interferon lambda receptor complex, driving type III interferon signaling at barrier tissues such as the gastrointestinal tract, respiratory tract, and liver. The lead disclosed indication is chronic norovirus enteritis in immunocompromised transplant recipients, and the program has also been described as being in development for chronic hepatitis B. Available public sources do not clearly disclose the exact molecular composition, sequence architecture, commercial brand name, or detailed clinical pharmacology beyond its classification as a potent, long-acting interferon lambda chimera.

Other names

interferon lambda chimera